Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes

Abstract

To the Editor: In the AMPLITUDE-O trial, Gerstein et al. (Sept. 2 issue)¹ found a lower risk of cardiovascular events among participants with type 2 diabetes who received a weekly injection of efpeglenatide than among those who received placebo. This trial confirms the interest in glucagon-like peptide-1 (GLP-1) receptor agonists in terms of cardiovascular protection in patients with type 2 diabetes.^2-5 However, some concerns persist regrading retinal safety, as observed with semaglutide in SUSTAIN-6 (Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes).³ Persons with severe retinal disease were excluded from the AMPLITUDE-O . . .